公开(公告)号：US11801290B2

公开(公告)日：2023-10-31

申请号：US16333596

申请日：2017-09-15

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Malcolm S. Duthie

IPC: A61K39/40 ,  A61K38/00 ,  A61K39/04 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/04 ,  A61K39/39 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577

Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.

公开(公告)号：US11369672B2

公开(公告)日：2022-06-28

申请号：US16126285

申请日：2018-09-10

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Rhea N. Coler

IPC: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.

公开(公告)号：US11376325B2

公开(公告)日：2022-07-05

申请号：US16899729

申请日：2020-06-12

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/395 ,  A61K39/39 ,  A61K39/008 ,  A61K45/06 ,  A61K39/04 ,  A61K39/145 ,  A61K39/00 ,  C12N7/00

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US11897922B2

公开(公告)日：2024-02-13

申请号：US17367812

申请日：2021-07-06

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Rhea N. Coler ,  Gregory C. Ireton ,  Sylvie Bertholet

IPC: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/569 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/5695 ,  G01N33/68 ,  A61K2039/55561 ,  C07K2319/00 ,  G01N2469/20 ,  Y02A50/30

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp.) antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US11801223B2

公开(公告)日：2023-10-31

申请号：US15108773

申请日：2014-12-29

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. Fox ,  Thomas Vedvick ,  Lucien Barnes V. ,  Ryan M. Kramer ,  Steven G. Reed

IPC: A61K9/19 ,  A61K39/00 ,  A61K47/26 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/10

CPC classification number: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/55572

Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

公开(公告)号：US11510875B2

公开(公告)日：2022-11-29

申请号：US14377488

申请日：2013-02-07

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher Fox ,  Steven G. Reed ,  Susan Baldwin ,  Thomas Vedvick

IPC: A61K9/113 ,  A61K39/39 ,  A61K39/015 ,  A61K39/12 ,  A61K9/107 ,  A61K47/06 ,  A61K39/00 ,  A61K47/24 ,  A61K47/26

Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.